SCHEMBL6702952

SCHEMBL6702952

CC(C)(C)[Si](C)(C)OCC1COc2c1ccnc2Nc1ncc(C#N)s1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.38
FFAR2 O15552 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705398 0.83 KDR (0.42) KDR
SCHEMBL5744563 0.75 KDR (0.52) KDRFFAR2
SCHEMBL26647051 0.72 DUT (0.32)
SCHEMBL26646832 0.72 P2RX7 (0.37)
SCHEMBL5745081 0.69 KDR (0.57) KDR
SCHEMBL6700794 0.68 KDR (0.46) KDR
SCHEMBL26647084 0.64
SCHEMBL5742382 0.64 KDR (0.48) KDR
SCHEMBL5744213 0.62 KDR (0.58) KDRFFAR2
SCHEMBL5741877 0.62 KDR (0.61) KDRFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235867-A1 Tyrosine kinase inhibitors BILODEAU MARK T (US) 2004-11-25 US disclosed
WO-2003009852-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235867-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KDR 5/4885FFAR2 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.